Clinical trials
Pancreatic Adenocarcinoma clinical trials
Below are recruiting pancreatic adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07845617Recruiting
Liver pump chemotherapy for cancer that has spread to the liver
This trial tests a treatment that delivers chemotherapy directly to the liver through a small pump. It is for people whose pancreatic or duodenal cancer has spread mainly to the liver, after they have had or are still getting treatment to try to cure the cancer.
Orlando, FloridaAges 18–80 - NCT06655233Recruiting
Exploring gut bacteria in pancreatic cancer tumors
This trial studies bacteria found inside pancreatic tumors to see if they can help diagnose or predict the course of the disease. You may be eligible if you have a suspected pancreatic cancer and need a special biopsy (EUS-FNB).
Hunan, HunanAges 18–80 - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT07769502RecruitingPhase 2
Treatment for advanced bile duct and pancreatic cancers
This trial is studying a new drug, telisotuzumab adizutecan, in combination with other treatments for advanced bile duct or pancreatic cancers. The goal is to see if the combination helps control the cancer. It's designed for people who are relatively active and can do their daily tasks.
Hattiesburg, MississippiAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT07630961RecruitingPhase 1
New PET Imaging Scans for Advanced Solid Tumors
This trial tests two new radioactive imaging scans (called PET scans) designed to better detect certain advanced cancers like pancreatic, lung, breast, colon, or soft-tissue tumors. The goal is to see if these scans help doctors find and track cancer more accurately than standard imaging.
Odense CAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07587866Recruiting
Panuri Test for Suspected Pancreatic Cancer
This study tests a new diagnostic tool called Panuri to help detect pancreatic cancer in adults who have symptoms suggesting the disease. The test may help doctors identify pancreatic cancer earlier and more accurately.
BékéscsabaAges 18 years+ - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07500259Recruiting
Personalized drug testing for GI tumors
This trial uses a lab test to see how your tumor responds to different drugs, helping doctors choose the best treatment for you. It is for people with pancreatic cancer (PDAC) who are having surgery or a biopsy.
Luxembourg, LuxembourgAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT07435038RecruitingPhase 1/Phase 2
Trial of BPI-572270 for advanced solid tumors with RAS mutations
This trial tests a new drug, BPI-572270, for people with advanced solid tumors that have specific changes in the RAS gene. It may be an option if you have already tried standard treatments for your cancer type.
Blacktown, New South WalesAges 18 years+ - NCT07432633RecruitingPhase 1/Phase 2
Imaging scan to detect cancer-linked protein in several tumor types
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Dallas, TexasAges 18–80 - NCT06782412RecruitingPhase 2/Phase 3
New imaging test for different cancers using FAPI-PET
This trial is testing a new imaging method called FAPI-PET to see if it can help find and understand tumors better than standard scans. It is for people with newly diagnosed stomach/esophageal cancer, pancreatic cancer, or those with unclear symptoms or scan results.
EdegemAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07373691Enrolling by invitation
Scoring system study for advanced pancreatic cancer
This study looks at a scoring system to predict how well people with advanced pancreatic cancer might do after their first chemotherapy. If you have been diagnosed with this type of cancer and are about to start or have just finished your first treatment, this study may be able to use your health information to help guide future care.
ShanghaiAges 18 years+ - NCT04374175Recruiting
Blood sample bank for pancreatic cancer patients and controls
This study collects and stores blood samples (“serum bank”) from people with pancreatic cancer and from comparison participants. The goal is to help researchers study the disease and improve future diagnosis or treatment planning.
Saint-EtienneAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Princeton, New JerseyAges 18 years+ - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma?
- Yes. Clin2 currently lists 346 recruiting pancreatic adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.